Kailera Q3 net loss widens to $95.7 million from $39.6 million a year earlier
Kailera Therapeutics reported a third-quarter 2026 net loss of $95.7 million, up from $39.6 million in the same period of 2025, as research and development and general and administrative expenses rose sharply. The company reported cash, cash equivalents and marketable securities of $1,037.6 million as of September 30, 2026, which it expects to fund operations into mid-2028.
Key points
- Q3 2026 R&D expenses were $84.7 million, up from $27.0 million a year earlier.
- Q3 2026 general and administrative expenses were $21.7 million, up from $13.1 million.
- Ribupatide oral global Phase 3 program is expected to begin in the first half of 2027, following an End-of-Phase 2 meeting with the U.S. FDA.
- Cash of $1,037.6 million is expected to fund operations into mid-2028.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.